NANOS3
Summary:
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| nanos C2HC-type zinc finger 3 | MIM:608229 | Ensembl:ENSG00000187556 | HGNC:HGNC:22048 | PA134867615 | 19p13.12 |
Gene Categories:
TUMOR SUPPRESSORGO terms in NANOS3
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | ISS | GO:0003723 | RNA binding |
| MF | IPI | GO:0005515 | protein binding |
| MF | IEA | GO:0008270 | zinc ion binding |
| CC | ISS | GO:0000932 | P-body |
| CC | IDA | GO:0005634 | nucleus |
| CC | IDA | GO:0005737 | cytoplasm |
| CC | ISS | GO:0010494 | cytoplasmic stress granule |
| CC | IDA | GO:0048471 | perinuclear region of cytoplasm |
| BP | ISS | GO:0006417 | regulation of translation |
| BP | IEA | GO:0007275 | multicellular organism development |
| BP | IMP | GO:0007281 | germ cell development |
| BP | ISS | GO:0007283 | spermatogenesis |
| BP | IDA | GO:0017148 | negative regulation of translation |
| BP | IEA | GO:0048477 | oogenesis |
| BP | ISS | GO:0051726 | regulation of cell cycle |
| BP | IDA | GO:1900153 | positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay |
| BP | IEA | GO:2001234 | negative regulation of apoptotic signaling pathway |
Gene expression in normal tissue: NANOS3
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in NANOS3
| Database | Pathway ID | Pathway Des. |
|---|
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD103 | SN-38 | 3 |
| iGMDRD158 | NSC141540 | 3 |
| iGMDRD271 | Brefeldin A | 1 |
| iGMDRD231 | Importazole | 1 |
| iGMDRD6 | AM-580 | 5 |
| iGMDRD105 | Triptolide | 1 |
| iGMDRD662 | JQ-1 | 2 |
| iGMDRD67 | PENFLURIDOL | 3 |
| iGMDRD286 | Nsc 632839 | 1 |
| iGMDRD367 | Ro 28-1675 | 3 |
| iGMDRD82 | Quiflapon | 1 |
| iGMDRD505 | Pevonedistat | 3 |
| iGMDRD246 | NPC26 | 4 |
| iGMDRD248 | BRD4354 | 3 |
| iGMDRD523 | Cyanoquinoline, 11 | 1 |
| iGMDRD79 | Gemcitabine | 3 |
| iGMDRD150 | RITA | 1 |
| iGMDRD345 | Compound 10b [PMID: 11504634] | 3 |
| iGMDRD57 | Chloropentafluorobenzene | 1 |
| iGMDRD351 | GW843682X | 1 |
| iGMDRD237 | ABT-751 | 1 |
| iGMDRD883 | CIL55A | 3 |
| iGMDRD132 | (-)-gallocatechin-3-O-gallate | 2 |
| iGMDRD154 | NSC23766 | 2 |
| iGMDRD211 | (1S,3R)-RSL3 | 6 |
| iGMDRD177 | Teniposide | 5 |
| iGMDRD123 | Isoevodiamine | 5 |
| iGMDRD138 | PX 12 | 3 |
| iGMDRD318 | PAC-1 | 1 |
| iGMDRD226 | ML006 | 1 |
| iGMDRD870 | BRD63610 | 4 |
| iGMDRD171 | Pemetrexed | 1 |
| iGMDRD577 | BIX01294 | 6 |
| iGMDRD888 | Compound 44 | 1 |
| iGMDRD100 | Zebularine | 3 |
| iGMDRD188 | Piperlongumine | 3 |
| iGMDRD399 | Selumetinib | 1 |
| iGMDRD74 | Idarubicin | 1 |
| iGMDRD887 | Compound 23 citrate | 1 |
| iGMDRD356 | PNU-74654 | 1 |
| iGMDRD451 | Serdemetan | 4 |
| iGMDRD64 | Parbendazole | 3 |
| iGMDRD60 | Quinoclamine | 2 |
| iGMDRD229 | B02 | 2 |
| iGMDRD1008 | SR-II-138A | 2 |
| iGMDRD579 | PF750 | 4 |
| iGMDRD126 | Tipifarnib | 2 |
| iGMDRD76 | Simvastatin | 2 |
| iGMDRD433 | Lexibulin | 4 |
| iGMDRD494 | Neopeltolide | 1 |
| iGMDRD670 | ML 210 | 5 |
| iGMDRD779 | PRL-3 Inhibitor I | 2 |
| iGMDRD427 | ABT737 | 8 |
| iGMDRD639 | YK 4-279 | 3 |
| iGMDRD193 | Fqi1 | 4 |
| iGMDRD2 | PK-11195 | 2 |
| iGMDRD446 | LY 2183240 | 3 |
| iGMDRD71 | Sparfosic acid | 2 |
| iGMDRD201 | SKI II | 1 |
| iGMDRD280 | CYTOCHALASIN B | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in NANOS3
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.